Multi-Omic Approaches in Cancer-Related Micropeptide Identification

Proteomes, Journal Year: 2024, Volume and Issue: 12(3), P. 26 - 26

Published: Sept. 13, 2024

Despite the advances in modern cancer therapy, malignant diseases are still a leading cause of morbidity and mortality worldwide. Conventional treatment methods frequently lead to side effects drug resistance patients, highlighting need for novel therapeutic approaches. Recent findings have identified existence non-canonical micropeptides, an additional layer proteome complexity, also called microproteome. These small peptides promising class agents with potential address limitations current treatments. The microproteome is encoded by regions genome historically annotated as non-coding, its has been revealed thanks recent proteomic bioinformatic technology, which dramatically improved understanding complexity. Micropeptides shown be biologically active several types, indicating their role. Furthermore, they characterized low toxicity high target specificity, demonstrating development better tolerated drugs. In this review, we survey landscape known micropeptides role progression or treatment, discuss anticancer agents, describe methodological challenges facing field research.

Language: Английский

Small non-coding RNAs as diagnostic, prognostic and predictive biomarkers of gynecological cancers: an update

Expert Review of Molecular Diagnostics, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 17

Published: Oct. 10, 2024

Introduction Non-coding RNAs (ncRNAs) comprise a heterogeneous cluster of RNA molecules. Emerging evidence suggests their involvement in various aspects tumorigenesis, particularly gynecological malignancies. Notably, ncRNAs have been implicated as mediators within tumor signaling pathways, exerting influence through interactions with or proteins. These findings further highlight the hypothesis that constitute therapeutic targets and point out clinical potential stratification biomarkers.

Language: Английский